{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:18:32Z","timestamp":1781659112767,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ymgmr.2021.100769","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T17:27:28Z","timestamp":1621963648000},"page":"100769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries"],"prefix":"10.1016","volume":"28","author":[{"given":"Villarreal M","family":"Solano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Yazm\u00edn Coss\u00edo","family":"Mandujano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Amor","family":"Avila-Rejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Hugo","family":"Espin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Paul Quintero","family":"Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2021.100769_bb0005","series-title":"Mucopolysaccharidosis, Medscape","first-page":"1","author":"Bittar","year":"2020"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0010","article-title":"Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases","author":"Gaffke","year":"2020","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1399-0004.1988.tb03421.x","article-title":"Clinical findings in 12 patients with MPS IV A (Morquio\u2019s disease)","volume":"33","author":"Nelson","year":"2008","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0020","series-title":"Online Mendelian Inheritance in Man (OMIM). Mucopolysaccharidosis type VI","author":"Johns Hopkins University","year":"2018"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0025","series-title":"Mucopolusaccharidosis Type IVA, Online Mendelian Inherit. Man (OMIM)","author":"Vernon","year":"2020"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","article-title":"Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues","volume":"11","author":"Hendriksz","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"5","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/891596","article-title":"Bisphosphonate treatment in a patient affected by MPS IVA with osteoporotic phenotype","volume":"2013","author":"Tummolo","year":"2013","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","article-title":"Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","article-title":"Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0055","article-title":"Current and emerging treatments and surgical interventions for Morquio A syndrome: a review","volume":"65","author":"Tomatsu","year":"2012","journal-title":"Res. Rep. Endocr. Disord."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymgme.2014.12.001","article-title":"Therapies for the bone in mucopolysaccharidoses","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0065","article-title":"Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome","volume":"1937","author":"Tomatsu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2017.12.434","article-title":"Gene therapy for Mucopolysaccharidoses","volume":"123","author":"Sawamoto","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0075","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","article-title":"Therapeutic options for Mucopolysaccharidoses: current and emerging treatments","volume":"79","author":"Sawamoto","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03635","article-title":"A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia","volume":"6","author":"Puentes-Tellez","year":"2020","journal-title":"Heliyon."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0085","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10545-011-9336-2","article-title":"Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world","volume":"34","author":"Mu\u00f1oz-Rojas","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0090","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1590\/S1415-47572012000600006","article-title":"Mucopolysacccharidoses: from understanding to treatment, a century of discoveries","volume":"35","author":"Giugliani","year":"2012","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0100","first-page":"27","article-title":"Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI","volume":"7","author":"Ahmed","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009806.pub2","article-title":"Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI","author":"Brunelli","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jcpt.12136","article-title":"Current and potential therapeutic strategies for mucopolysaccharidoses","volume":"39","author":"Noh","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","article-title":"Enzyme replacement and enhancement therapies for lysosomal diseases","volume":"27","author":"Desnick","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0125","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/17512433.2017.1260000","article-title":"Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio a syndrome)","volume":"9","author":"Hendriksz","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0130","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio a syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0135","series-title":"Disabilities Inclusive Education Systems and Policies Guide for Low- and Middle-Income Countries","author":"Hayes","year":"2017"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00431-019-03330-x","article-title":"Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion","volume":"178","author":"Guffon","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0145","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajmg.a.32281","article-title":"Growth charts for patients affected with Morquio a disease","volume":"146A","author":"Monta\u00f1o","year":"2008","journal-title":"Am. J. Med. Genet. Part A."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0150","series-title":"JIMD Rep, 2014\/12\/19","first-page":"1","article-title":"Growth charts for individuals with Mucopolysaccharidosis VI (Maroteaux\u2013Lamy Syndrome)","author":"Quartel","year":"2014"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13052-018-0551-4","article-title":"Clinical hints to diagnosis of attenuated forms of Mucopolysaccharidoses","volume":"44","author":"Rigoldi","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0160","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13023-016-0521-0","article-title":"Parents\u2019 experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS)","volume":"11","author":"Somanadhan","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International Morquio a registry: clinical manifestation and natural course of Morquio a disease","volume":"30","author":"Monta\u00f1o","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0170","series-title":"Maroteaux Lamy Syndrome","author":"National Organization for Rare Disorders (NORD)","year":"2020"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0175","doi-asserted-by":"crossref","first-page":"e20180658","DOI":"10.1542\/peds.2018-0658","article-title":"Diagnosis of attenuated Mucopolysaccharidosis VI: clinical, biochemical, and genetic pitfalls","volume":"142","author":"Pinto e Vairo","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0180","article-title":"Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I","author":"Giugliani","year":"2020","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0185","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0190","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/mt.2010.32","article-title":"Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio a syndrome","volume":"18","author":"Tomatsu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0195","series-title":"Department of Economic and Social Affers, Population Division, World Urbanization Prospects: The 2018 Revision","author":"United Nations","year":"2018"},{"key":"10.1016\/j.ymgmr.2021.100769_bb0200","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ymgme.2011.09.017","article-title":"Genetic studies in a cluster of Mucopolysaccharidosis type VI patients in Northeast Brazil","volume":"104","author":"Costa-Motta","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0205","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3390\/ijms21041204","article-title":"Underestimated aspect of Mucopolysaccharidosis pathogenesis: global changes in cellular processes revealed by Transcriptomic studies","volume":"21","author":"Gaffke","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0210","first-page":"87","article-title":"Psychological health in adults with morquio syndrome","volume":"20","author":"Ali","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajmg.a.36833","article-title":"International guidelines for the management and treatment of Morquio A syndrome","volume":"167","author":"Hendriksz","year":"2015","journal-title":"Am. J. Med. Genet. Part A."},{"key":"10.1016\/j.ymgmr.2021.100769_bb0220","doi-asserted-by":"crossref","DOI":"10.1177\/2326409815616392","article-title":"Obstructive Sleep Apnea in MPS","volume":"3","author":"Pal","year":"2015","journal-title":"J. Inborn Errors Metab. Screen."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692100063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692100063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:00Z","timestamp":1762001520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221442692100063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":44,"alternative-id":["S221442692100063X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100769","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100769"}}